References
- Boger LA, Volker LL, Hertenstein GK, et al. Best patient preparation before and during radionuclide myocardial perfusion imaging studies. J Nucl Cardiol 2006;13:98-110
- Henzlova MJ, Cerqueira MD, Hansen CL, et al. Stress protocols and tracers. J Nucl Cardiol 2009;16:331
- Johnson SG, Peters S. Advances in pharmacologic stress agents: focus on regadenoson. J Nucl Med Technol 2010;38:163-71
- Hendel RC, Bateman TM, Cerqueira MD, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75
- Husain Z, Palani G, Cabrera R, et al. Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging 2011;28:1841-9
- Reyes E, Staehr P, Olmsted A, et al. Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. J Nucl Cardiol 2011;18:620-7
- Hudgens S, Kothari S, Spalding J. Development of a Patient-Reported Outcome Measure and a Clinician-Reported Outcome Measure to assess satisfaction and preference with pharmacological stress agents for Single Photon Emission Computed Tomography Myocardial Perfusion Imaging. ISOQOL 18th Annual Congress, Denver, CO. 2011;A255
- Hudgens S, Kothari S. Validation of a Patient-Reported Outcome (PRO) Measure and a Clinician-Reported Outcome (CRO) Measure to Assess Satisfaction and preference with pharmacological stress agents for Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI). ISPOR 14th Annual European Congress, Madrid, Spain. 2011;PMD62
- Buhr C, Gossl M, Erbel R, et al. Regadenoson in the detection of coronary artery disease. Vasc Health Risk Manag 2008;4:337-40
- Prenner BM, Bukofzer S, Behm S, et al. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92
- Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58
- Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 2009;54:1635